A Phase 2a, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of PTl-125 in Mild-to-moderate Alzheimer's Disease Patients
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs PTI-125 (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacokinetics
- Sponsors Cassava Sciences
- 09 Sep 2019 Results presented in the Cassava Sciences media release.
- 09 Sep 2019 According to an Cassava Sciences Media Release, the company expects to present full data sets from this trial at Clinical Trials on Alzheimer's Disease (CTAD), a conference for the medical and scientific community being held in San Diego, CA, December 4-7th, 2019.
- 09 Sep 2019 According to an Cassava Sciences Media Release, this study was supported by the National Institute on Aging at NIH under award AG060878.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History